Navigation Links
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/7/2008

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference, which is being held November 10-12, 2008 at the New York Palace Hotel in New York, NY. Mr. Burns' presentation is scheduled for Tuesday, November 11, 2008 at 2:25 p.m. (local time).

Mr. Burns' presentation will be web cast and, as previously announced, will serve as the Company's third quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &

Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... AZ (PRWEB) , ... May ... ... Actûrus , is happy to announce the launch of its brand ... the funnel model to reflect the dynamic landscape of modern consumer decision-making. ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Development Team ... Plugin for FCPX. , "This new layered style transition tool will keep a ... Austion - CEO of Pixel Film Studios. , TranSweep is an all new ...
(Date:5/26/2016)... ... 2016 , ... In Madeira Beach Florida, a small town with 4,300 residents ... an organization, Madeira Beach United, to oppose two development projects undertaken by their city ... a high rise urban environment. , According to the Tampa Bay Times ...
(Date:5/26/2016)... Portland, OR (PRWEB) , ... May 26, 2016 , ... ... social customs. In an industry filled with chemical-laden beauty products, one company is going ... importantly, good for you: Mad Hippie. The rising star in the green space is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic apparel company GRACEDBYGRIT ... pop-up shop for three consecutive weekends. The pop-up shop is a great way ... a community full of women who appreciate the most premium goods and vibrant ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Cirujanos holandeses han puesto en marcha ... a compartir sus mejores prácticas por el mundo y ... de Europa, África, Asia y ... que combina la transmisión en vivo con mensajería instantánea ... Educación   "Imagine un médico de Medicines sans ...
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: